TB PRACTECAL: launch event
In Nukus, Karakalpakstan, in the west of Uzbekistan, we treat patients for tuberculosis (TB) under the PRACTECAL clinical trial.

The trial combines the first new TB drugs available in over 50 years with existing drugs to treat drug-resistant forms of the disease. Uzbekistan is among the top 27 countries with the highest rates of multidrug-resistant TB (MDR-TB).

We also treat children with TB with a shorter regimen of nine months, instead of the usual 12 months or more, and is conducting research into the results.

In the capital, Tashkent, we support the regional AIDS centre, with the aim of increasing access to diagnosis and care for patients living with HIV and treating co-infections.

We are currently responding to the coronavirus COVID-19 pandemic in the country.

In 2019
Journal article

Impact of pyrazinamide resistance on multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan

1 May 2018
Journal article
DR TB Treatment in Uzbekistan
Access to medicines

Pioneering clinical trial for drug-resistant tuberculosis starts

Press Release 19 Jan 2017

“Please, never give up. You too can beat TB.”

Voices from the Field 6 Aug 2015
Journal article

Risk Factors Associated with Default from Multi- and Extensively Drug-Resistant Tuberculosis Treatment, Uzbekistan: A Retrospective Cohort Analysis

6 Nov 2013
Journal article

Comprehensive TB care for all: The Karakalpakstan Experience

Report 2 May 2011

Meet the first MSF patient to have recovered from XDR-TB

Project Update 23 Dec 2010